SCHEMBL3138382

SCHEMBL3138382

CC(C)(C)[Si](C)(C)OCc1ccc(C(N)=NO)o1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.35
RAB9A P51151 9/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
GAA P10253 1/20 0.31
PKM P14618 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSP90AA1 P07900 1/20 0.31
TSHR P16473 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3138375 1.00 NPC1 (0.35) NPC1RAB9AALDH1A1LMNAKMT2A
SCHEMBL30688991 0.78 DUT (0.34) NPC1RAB9A
SCHEMBL3138386 0.74 NPC1 (0.36) NPC1RAB9AALDH1A1LMNAKMT2A
SCHEMBL7471846 0.73 BACE1 (0.36) NPC1RAB9AALDH1A1MAPTTDP1
SCHEMBL3134668 0.73 NPSR1 (0.31) RAB9AGAA
SCHEMBL3134676 0.73 NPSR1 (0.31) RAB9AGAA
SCHEMBL31263367 0.73 CHRM2 (0.42) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL3147047 0.71 F2 (0.32) ALDH1A1
SCHEMBL3128598 0.71 F2 (0.32) ALDH1A1
SCHEMBL9969768 0.71 RAB9A (0.43) NPC1RAB9AALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687491-B2 Heterocyclic compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-03-30 US disclosed
US-20080113961-A1 Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113961-A1 Immunosuppressants with low toxicity; 1-({4-Methyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl}methyl)azetidine-3-carboxylic acid for example; autoimmune diseases and transplant rejection; N-substituted azetidine, pyrrolidine or piperidine compounds TPMT, AZI2, IDO1 NPC1 1258/4885RAB9A 202/4885ALDH1A1 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.